BEDFORD, Mass.--(BUSINESS WIRE)--Sep. 25, 2017--
Ocular Therapeutix™, Inc. (NASDAQ:OCUL), a biopharmaceutical company
focused on the development, manufacturing and commercialization of
innovative therapies for diseases and conditions of the eye, today
announced the appointment of Donald Notman as Chief Financial Officer,
effective immediately. With over 20 years of financial operations and
senior-level investment banking experience, Mr. Notman brings a
distinguished track record of success to Ocular Therapeutix. Mr. Notman
will replace interim CFO George Migausky and will be responsible for all
strategic financial planning and reporting and investor relations. He
will also support the Company’s business development initiatives.
“Donald brings an extensive financial background as well as a wealth of
experience and relationships ideally suited to Ocular Therapeutix,” said
Antony Mattessich, President and Chief Executive Officer. “He will be a
strong complement to our existing team and his expertise will be
invaluable as we focus our efforts on leveraging our hydrogel technology
platform to build a leading biopharmaceutical company. We would also
like to thank George for his many contributions as interim CFO over the
last several months and wish him all the best.”
Prior to joining Ocular Therapeutix, Mr. Notman served as Senior Vice
President and Chief Financial Officer of Thrasos Therapeutics Inc.,
where he led the Company’s financial operations, business development
activities, and strategic planning functions. Previously, Mr. Notman
served as Managing Director and Head of Private Capital Markets for
Leerink Swann LLC (now Leerink Partners), where he was involved in the
build-out of the firm’s healthcare investment banking capabilities.
Before joining Leerink, Mr. Notman held senior level investment banking
positions with Deutsche Banc Alex. Brown and Alex. Brown & Sons. Mr.
Notman received his M.B.A. from The Tuck School of Business at Dartmouth
College and his B.A. in Economics from Middlebury College.
“Ocular’s innovative hydrogel technology platform along with the team’s
formulation and product development expertise provide Ocular with the
ability to leverage the platform in a number of ways to advance the
Company,” stated Mr. Notman. “I look forward to applying my background
and expertise to help Ocular achieve its full potential.”
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the
development, manufacturing and commercialization of innovative therapies
for diseases and conditions of the eye using its proprietary hydrogel
platform technology. Ocular Therapeutix’s lead product candidate,
DEXTENZA™ (dexamethasone insert) 0.4 mg for intracanalicular use, has
completed Phase 3 clinical development for the treatment of ocular pain
and inflammation following ophthalmic surgery. OTX-TP (travoprost
insert) is in Phase 3 clinical development for glaucoma and ocular
hypertension. The Company’s earlier stage assets include OTX-TIC, a
sustained release travoprost intracameral injection for the treatment of
moderate to severe glaucoma and ocular hypertension, as well as
sustained release intravitreal injections for the treatment of retinal
diseases. These injections include the development of OTX-TKI, a
tyrosine kinase inhibitor (TKI), and, in collaboration with Regeneron,
an extended release protein-based anti-vascular endothelial growth
factor (VEGF) trap. Ocular Therapeutix's first product, ReSure® Sealant,
is FDA-approved to seal corneal incisions following cataract surgery.
Forward Looking Statements
Any statements in this press release about future expectations, plans
and prospects for the Company including the development and regulatory
status of the Company’s product candidates, such as the Company’s
expectations and plans regarding product development efforts and
regulatory submissions for and the timing and conduct of clinical trials
of DEXTENZA for the treatment of post-surgical ocular inflammation and
pain, including with respect to the manufacturing deficiencies
identified by the FDA and the prospects for approvability of DEXTENZA
for these indications, DEXTENZA for the treatment of allergic
conjunctivitis, DEXTENZA for the treatment of dry eye disease and OTX-TP
for the treatment of glaucoma and ocular hypertension, the ongoing
development of the Company’s sustained release intravitreal depot, the
potential utility of any of the Company’s product candidates, potential
commercialization of the Company’s product candidates, the sufficiency
of the Company’s cash resources, and other statements containing the
words "anticipate," "believe," "estimate," "expect," "intend", "goal,"
"may", "might," "plan," "predict," "project," "target," "potential,"
"will," "would," "could," "should," "continue," and similar expressions,
constitute forward-looking statements within the meaning of The Private
Securities Litigation Reform Act of 1995. Actual results may differ
materially from those indicated by such forward-looking statements as a
result of various important factors. Such forward-looking statements
involve substantial risks and uncertainties that could cause the
Company’s clinical development programs, future results, performance or
achievements to differ significantly from those expressed or implied by
the forward-looking statements. Such risks and uncertainties include,
among others, those related to the timing and costs involved in
commercializing ReSure® Sealant or any product candidate that receives
regulatory approval, the initiation and conduct of clinical trials,
availability of data from clinical trials and expectations for
regulatory submissions and approvals, the Company’s manufacturing
operations, the Company’s scientific approach and general development
progress, the availability or commercial potential of the Company’s
product candidates, the availability of cash resources and need for
additional financing or other actions and other factors discussed in the
“Risk Factors” section contained in the Company’s quarterly and annual
reports on file with the Securities and Exchange Commission. In
addition, the forward-looking statements included in this press release
represent the Company’s views as of the date of this release. The
Company anticipates that subsequent events and developments will cause
the Company’s views to change. However, while the Company may elect to
update these forward-looking statements at some point in the future, the
Company specifically disclaims any obligation to do so. These
forward-looking statements should not be relied upon as representing the
Company’s views as of any date subsequent to the date of this release.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170925005665/en/
Source: Ocular Therapeutix, Inc.
Investors
Burns McClellan
Steve Klass, 212-213-0006
sklass@burnsmc.com
or
Ocular
Therapeutix
Donald Notman
Chief Financial Officer
dnotman@ocutx.com
or
Media
Ocular
Therapeutix
Scott Corning
Vice President of Marketing &
Commercial Operations
scorning@ocutx.com